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Oxidative stressMitochondria are uniquely poised to play a pivotal role in neuronal cell survival or death because they are
regulators of both energy metabolism and cell death pathways. Extensive literature exists supporting a role
for mitochondrial dysfunction and oxidative damage in the pathogenesis of Alzheimer's disease. This review
discusses evidence indicating that mitochondrial dysfunction has an early and preponderant role in
Alzheimer's disease. Furthermore, the link between mitochondrial dysfunction and autophagy in Alzheimer's
disease is also discussed. As a result of insufﬁcient digestion of oxidatively damaged macromolecules and
organelles by autophagy, neurons progressively accumulate lipofuscin that could exacerbate neuronal
dysfunction. Since autophagy is the major pathway involved in the degradation of protein aggregates and
defective organelles, an intense interest in developing autophagy-related therapies is growing among the
scientiﬁc community. The ﬁnal part of this review is devoted to discuss autophagy as a potential target of
therapeutic interventions in Alzheimer's disease pathophysiology.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD) is the most common form of dementia
and affects millions of people worldwide. The disorder is character-
ized by severe memory loss, with episodic memory being particularly
impaired during the initial phases. Most AD cases occur sporadically,
although inheritance of certain susceptibility genes enhances the risk.
Familial AD represents the minority of AD cases and is caused by
mutations in genes encoding for either the amyloid β precursor
protein (AβPP), presenilin 1 (PS1), or presenilin 2 (PS2). Two
pathological hallmarks are observed in AD brains at autopsy:
intracellular neuroﬁbrillary tangles (NFTs) and extracellular senile
plaques (SP) in the neocortex, hippocampus, and other subcortical
regions essential for cognitive function. NFTs are formed from paired
helical ﬁlaments composed of neuroﬁlaments and hyperphosphory-
lated tau protein. In turn, plaque cores are formed mostly from
deposition of amyloid β (Aβ) peptide that results from the cleavage of
the AβPP.
The literature shows that mitochondrial dysfunction and oxidative
stress play an important role in the early pathology of AD [1–4].
Indeed, there are strong indications that oxidative stress occurs prior
to the onset of symptoms in AD and oxidative damage is found not
only in the vulnerable regions of the brain affected in disease [5–7] but
also peripherally [8–11]. Moreover, it has been shown that oxidative
damage occurs before Aβ plaque formation [5] supporting a causative+1 210 458 4445.
ll rights reserved.role of mitochondrial dysfunction and oxidative stress in AD. This
review is mainly devoted to discuss evidence showing that mito-
chondrial dysfunction and oxidative stress is intimately involved in
AD pathogenesis. Furthermore, the interplay between mitochondrial
abnormalities and autophagy in AD will be addressed. Finally, we will
brieﬂy discuss autophagy as a potential target of therapeutic
interventions in AD pathophysiology.
2. The good and the bad side of brain mitochondria
Although the brain represents only 2% of the body weight, it
receives 15% of cardiac output and accounts for 20% of total body
oxygen consumption. This energy requirement is largely driven by
neuronal demand for energy to maintain ion gradients across the
plasma membrane that is critical for the generation of action
potentials. This intense energy requirement is continuous; even
brief periods of oxygen or glucose deprivation result in neuronal
death.
Mitochondria are increasingly recognized as subcellular organelles
that are essential for generating the energy that fuels normal cellular
function while, at the same time, they monitor cellular health in order
to make a rapid decision (if necessary) to initiate programmed cell
death (Fig. 1). As such, the mitochondria sit at a strategic position in
the hierarchy of cellular organelles to continue the healthy life of the
cell or to terminate it. Mitochondria are essential for neuronal
function because the limited glycolytic capacity of these cells makes
them highly dependent on aerobic oxidative phosphorylation
(OXPHOS) for their energetic needs. However, OXPHOS is a major
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(H2O2), hydroxyl (HOU) and superoxide (O2−U) radicals that are
products of normal cellular respiration (Fig. 1).
With inhibition of electron transport chain (ETC), electrons
accumulate in complex I and coenzyme Q, where they can be donated
directly to molecular oxygen to give O2−U that can be detoxiﬁed by the
mitochondrial manganese superoxide dismutase (MnSOD) to give
H2O2 that, in turn, can be converted to H2O by glutathione peroxidase
(GPx). However, O2−U in the presence of nitric oxide (NOU), formed
during the conversion of arginine to citrulline by nitric oxide synthase
(NOS), can lead to peroxynitrite (ONOO−). Furthermore, H2O2 in the
presence of reduced transition metals can be converted to toxic HOU
via Fenton and/or Haber Weiss reactions. Several efﬁcient enzymatic
processes are continuously operational to quench the reactive species
including SOD, GPx, superoxide reductase (SRed), catalase (CAT),
peroxiredoxin (Prx), thioredoxin/thioredoxin reductase (Trx/
TrxRed) [12]. Inevitably, if the amount of free radical species produced
overwhelms the neuronal capacity to neutralize them, oxidative stress
occurs, followed by mitochondrial dysfunction and neuronal damage.
Reactive species generated by mitochondria have several cellular
targets including mitochondrial components themselves (lipids,
proteins, and DNA). The lack of histones in mitochondrial DNAFig. 1. Dual role of mitochondria. Besides the fundamental role of mitochondria in the gen
radicals. If the defensemechanisms are debilitated these reactive species initiate a cascade of
H2O2, hydrogen peroxide; mtDNA, mitochondrial DNA; O2−U, superoxide anion radical; e-, e(mtDNA) and the diminished capacity for DNA repair render the
mitochondria an easy target to oxidative stress events.
The central nervous system (CNS) is particularly susceptible to
reactive species-induced damage [13] because (1) it has a high
consumption of oxygen, (2) it contains high levels of membrane
polyunsaturated fatty acids susceptible to free radical attack, (3) it is
relatively deﬁcient in oxidative defenses (poor CAT activity and
moderate SOD and GPx activities), and (4) a high content in iron and
ascorbate can be found in some regions of the CNS, enabling
generation of more reactive species through the Fenton/Haber
Weiss reactions.
Mitochondria also serve as high-capacity Ca2+ sinks, which allows
them to stay in tune with changes in cytosolic Ca2+ loads and aid in
maintaining cellular Ca2+ homeostasis that is required for normal
neuronal function [14]. Conversely, excessive Ca2+ uptake into
mitochondria has been shown to increase ROS production, inhibit
ATP synthesis, induce mitochondrial permeability transition pore
(PTP), and release small proteins that trigger the initiation of
apoptosis, such as cytochrome c and apoptosis-inducing factor (AIF),
from the mitochondrial intermembrane space into the cytoplasm.
Released cytochrome c binds apoptotic protease-activating factor 1
(Apaf-1) and activates the caspase cascade [15]. Such alterations ineration of energy (ATP), these organelles are also the main producers of oxygen free
deleterious events within the cell. See text for more detail. ETC, electron transport chain;
lectrons; O2, molecular oxygen.
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in the pathogenesis of AD (Fig. 2).
3. Mitochondrial dysfunction is an early event in AD
Swerdlow and Khan [16,17] proposed the mitochondrial cascade
hypothesis to explain late-onset, sporadic AD. In short, this hypothesis
states that, in the sporadic AD, mitochondrial dysfunction is the
primary event that causes Aβ deposition, synaptic degeneration, and
NFTs formation. Indeed, there is a bulk of studies showing that
mitochondrial dysfunction is a common event in AD.
Using in situ hybridization to mtDNA, immunocytochemistry of
cytochrome oxidase (COX), and morphometry of electron micro-
graphs of biopsy specimens, we demonstrated that neurons showing
increased oxidative damage in AD also possessed a striking and
signiﬁcant increase in mtDNA and COX [18,19]. Moreover, we found
that much of the mtDNA and COX was localized in the neuronal
cytoplasm and, in the case of mtDNA, in vacuoles associated with
lipofuscin, whereasmorphometric analysis showed thatmitochondria
were signiﬁcantly reduced in AD. Interestingly, the cellular expressionFig. 2.Mitochondrial dysfunction in Alzheimer's disease. Mitochondrial abnormalities assoc
cell degeneration and death that occur in Alzheimer's disease. Indeed, during Alzheimer
generation of adenosine triphosphate (ATP) and enhanced production of reactive oxygen spe
in a cascade of deleterious within the cell. Impaired mitochondria also release several pro-a
apoptosis by associating with cytosolic factors to form the apoptosome. Finally, some mitoch
acid (DNA) fragmentation. Altogether, these mitochondrial alterations contribute to cell deg
1; dATP, 2′-deoxyadenosine 5′-triphosphate; ROS, reactive oxygen species; ADP, adenosine
O2
U-, superoxide anion radical.of COX subunits II and IV is reduced during aging and these age-
related changes are moremarked in AD [20], suggesting that aging is a
major risk factor for this disease. However, Cottrell et al. [21] observed
that the distribution of amyloid plaques is anatomically distinct from
the COX-deﬁcient hippocampal pyramidal neurons, and the neurons
containing NFT or apoptotic labeling were always COX-positive. The
authors concluded that COX-deﬁcient, succinate dehydrogenase-
positive hippocampal neurons indicative of high mtDNA mutation
load do not appear to be prone to apoptosis or to directly participate in
the overproduction of tau or Aβ [21].
Wang et al. [22] quantiﬁed multiple oxidized bases in nuclear DNA
and mtDNA of frontal, parietal, and temporal lobes and cerebellum
from short postmortem interval AD brain and age-matched control
subjects using gas chromatography/mass spectrometry with selective
ion monitoring and stable labeled internal standards. It was found
that levels of multiple oxidized bases in AD brain specimens were
signiﬁcantly higher in frontal, parietal, and temporal lobes compared
to control subjects and that mtDNA had approximately 10-fold higher
levels of oxidized bases than nuclear DNA. These data are consistent
with higher levels of oxidative stress in mitochondria. Furthermore,iated with enhanced oxidative stress have long been recognized to play a major role in
's disease evolution, mitochondria suffer profound alterations that lead to a reduced
cies (ROS). Mitochondria also lose calcium (Ca2+) buffering capacity, which can initiate
poptotic factors upon induction of apoptosis. These factors are either directly triggering
ondrial, pro-apoptotic proteins translocate into the nucleus to induce deoxyribonucleic
eneration and death. AIF, apoptosis-inducing factor; APAF-1, protease-activating factor
diphosphate; H+, protons; H2O, water; Pi, inorganic phosphate; O2, molecular oxygen;
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higher than other oxidized base adducts in both AD and control
subjects. DNA from temporal lobe showed themost oxidative damage,
whereas cerebellum was only slightly affected in AD brains [22].
Altogether, these results suggest that oxidative damage tomtDNAmay
contribute to the neurodegeneration of AD. More recently, Baloyannis
[23] reported that, in AD cases, mitochondrial pathology correlates
substantially with the dystrophic dendrites, the loss of dendritic
branches, and the pathological alteration of the dendritic spines.
The mitochondrial abnormalities observed in the brains of AD
subjects are corroborated by animal studies. Indeed, Hauptmann et al.
[24] reported that mitochondrial dysfunction is an early event in mice
bearing the human Swedish and London mutations and these
mitochondrial defects accumulate with age. Recently, Fu et al. [25]
also reported that aging potentiates the mitochondrial abnormalities
occurring in PS1 transgenic (Tg) mice. Previous studies also demon-
strated that themitochondrial abnormalities appear to be key features
during the maturation of AD-like pathology in YAC and C57B6/SJL Tg
mice. A higher degree of amyloid deposition, overexpression of
oxidative stress markers, mtDNA deletion, and mitochondrial struc-
tural abnormalities in the vascularwalls of YAC and C57B6/SJL Tgmice
was observed when compared to age-matched controls [26,27].
Furthermore, Devi et al. [28] reported that AβPP, due to its
chimeric NH2-terminal signal, is targeted to cortical neuronal
mitochondria in a Tg mouse model of AD and the accumulation of
full-length AβPP in the mitochondrial compartment in a membrane-
arrested form causes mitochondrial dysfunction and impaired energy
metabolism. More recently, the same group reported that AβPP
accumulates exclusively in the protein import channels of mitochon-
dria of human AD brains [29]. The accumulation of AβPP across
mitochondrial import channels inhibits the entry of nuclear-encoded
COX subunits IV and Vb proteins, which decreases COX activity and
increases H2O2 levels. The levels of translocationally arrested
mitochondrial AβPP directly correlate with mitochondrial dysfunc-
tion. Moreover, apolipoprotein genotype analysis revealed that AD
subjects with the E3/E4 alleles have the highest content of
mitochondrial AβPP [29].
It has been shown that cultured neurons isolated from Tgmice that
overexpress a mutant form of AβPP and Aβ-binding alcohol
dehydrogenase (ABAD) (Tg mAβPP/ABAD) display reduced levels of
brain ATP and COX activity, diminished glucose utilization, as well as
electrophysiological abnormalities in hippocampal slices compared
with Tg mAβPP mice [29]. In contrast, neither Tg ABAD mice nor non-
Tg littermates showed similar changes in ATP, COX activity, glucose
utilization, or electrophysiological properties [30]. The same authors
also reported that cultured neurons isolated from Tg mAβPP/ABAD
display spontaneous generation of H2O2 and O2−U, decreased ATP,
release of cytochrome c, and induction of caspase 3-like activity
followed by DNA fragmentation and loss of cell viability. Furthermore,
generation of ROS is associated with dysfunction at the level of COX
[30]. These ﬁndings link ABAD-induced oxidant stress to critical
aspects of AD-associated cellular dysfunction, suggesting a pivotal
role for this enzyme in the pathogenesis of AD.
Takuma et al. [31] performed a comparative study using mice
deﬁcient in caspase 3 versus wild-type mice. They microinjected Aβ1–
40 into hippocampal regions of the brain of adult mice and found a
signiﬁcant cellular loss in the hippocampal regions of wild-type mice
and a dramatic rescue of neuronal cell death in caspase 3-deﬁcient
mice, with gene dosage effect. Furthermore, they observed that Aβ
induced a small amount of cell death in cultured neurons prepared
from fetal brain of caspase 3-deﬁcient mice; however, cells fromwild-
type mice suffered a drastic decrease in cell viability. These results
suggest that Aβ-induced neuronal death is mediated by caspase 3
apoptotic cascade. Kaminsky and Kosenko [32] investigated the in
vivo effects of Aβ peptides on mitochondrial and non-mitochondrial
enzymatic sources of ROS and antioxidant enzymes in rat brain. Theauthors observed that the continuous intracerebroventricular infu-
sion of both Aβ25–35 and Aβ40 for up to 14 days stimulated H2O2
generation in isolated neocortex mitochondria. Infusion of Aβ40 led to
an increase in MnSOD activity and a decrease in activities of CAT and
GPx in mitochondria and to an increase in Cu/ZnSOD and aldehyde
oxidase activities and promoted the conversion of xanthine dehydro-
genase to xanthine oxidase leading to an increase in the rate of H2O2
formation in the cytosol [32]. Resende et al. [33] reported that the
triple Tg mouse model of AD present decreased levels of GSH and
vitamin E and increased levels of lipid peroxidation. Additionally, the
authors observed an increased activity of the antioxidant enzymes
GPx and SOD [33]. These alterations are evident during the Aβ
oligomerization period, before the appearance of Aβ plaques and
NFTs, supporting the view that oxidative stress occurs early in the
development of the disease. David et al. [34] observed that Tg mice
overexpressing the P301 L mutant human tau protein present
alterations of metabolism-related proteins including mitochondrial
respiratory chain complex components, antioxidant enzymes, and
synaptic proteins that are associated with increased oxidative stress.
Furthermore, the authors observed that mitochondria from these Tg
mice displayed increased vulnerability toward Aβ insult, suggesting a
synergistic action of tau and Aβ pathology on the mitochondria. The
authors suggest that tau pathology involves a mitochondrial and
oxidative stress disorder possibly distinct from that caused by Aβ [34].
A panoply of in vitro studies corroborates the idea that mitochon-
dria are key players in AD. It has been previously shown that Aβ
requires functional mitochondria to induce toxicity [35]. Furthermore,
Hansson et al. [36] identiﬁed an active γ-secretase complex in rat
brain mitochondria. Being composed by nicastrin (NCT), anterior
pharynx-defective-1 (APH-1), and presenilin enhancer protein 2
(PEN2), this γ-secretase complex cleaves, among other substrates,
AβPP generating Aβ and AβPP intracellular domain. Furthermore, the
presence of AβPP was detected in mitochondrial membranes of PC12
cells bearing the Swedish double mutation in AβPP gene [37].
Altogether, these studies placed mitochondria in a privileged position
concerning AβPP processing and answered the “old question” of how
Aβ interacts with mitochondria.
Mitochondria continuously undergo two opposing processes:
ﬁssion and fusion. The disruption of this dynamic equilibrium may
herald cell injury or death and may contribute to neurodegenerative
disorders. Recently, Wang et al. [38] reported that sporadic AD
ﬁbroblasts present alterations in mitochondrial morphology and
distribution. They also demonstrated that the mitochondrial abnor-
malities are due to a decrease in dynamin-like protein 1 (DLP1), a
regulator of mitochondrial ﬁssion and distribution. The same authors
also demonstrated that elevated oxidative stress and increased Aβ
production are likely the potential pathogenic factors that cause DLP1
reduction and abnormal mitochondrial distribution in AD cells [38].
The same group investigated the effect of AβPP and Aβ on
mitochondrial dynamics in neurons [39]. Confocal and electron
microscopic analysis demonstrated that approximately 40% M17
cells overexpressing WT APP (AβPPwt M17 cells) and more than 80%
M17 cells overexpressing APPswe mutant (AβPPswe M17 cells)
displayed alterations in mitochondrial morphology and distribution.
Thesemitochondrial changeswere abolished by treatmentwith β-site
AβPP-cleaving enzyme inhibitor IV. From a functional perspective,
AβPP overexpression affected mitochondria at multiple levels,
including elevating ROS levels, decreasing mitochondrial membrane
potential, and reducing ATP production, and also caused neuronal
dysfunction such as differentiation deﬁciency upon retinoic acid
treatment. At the molecular level, levels of DLP1 and OPA1 were
signiﬁcantly decreased whereas levels of Fis1 were signiﬁcantly
increased in AβPPwt and AβPPsweM17 cells. Notably, overexpression
of DLP1 in these cells rescued the abnormal mitochondrial distribu-
tion and differentiation deﬁciency but failed to rescue mitochondrial
fragmentation and functional parameters, whereas overexpression of
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meters but failed to restore normal mitochondrial distribution.
Overexpression of AβPP or Aβ-derived diffusible ligand treatment
also led to mitochondrial fragmentation and reduced mitochondrial
coverage in neuronal processes in differentiated primary hippocampal
neurons. The authors concluded that AβPP, through Aβ production,
causes an imbalance of mitochondrial ﬁssion/fusion that results in
mitochondrial fragmentation and abnormal distribution, which
contributes to mitochondrial and neuronal dysfunction [39]. More
recently, Cho et al. [40] found that NOU produced in response to Aβ
triggered mitochondrial ﬁssion, synaptic loss, and neuronal damage,
in part via S-nitrosylation of DLP1 (forming SNO-DLP1). Preventing
nitrosylation of DLP1 by cysteine mutation abrogated these neuro-
toxic events. SNO-DLP1 is increased in brains of human AD patients
and may thus contribute to the pathogenesis of neurodegeneration.
Previous in vitro studies also showed that Aβ peptides in the
presence of Ca2+ exacerbate the opening of mitochondrial PTP
[41,42]. The PTP induction, a phenomenon characterized by a sudden
increase in the permeability of the inner mitochondrial membrane,
plays a key role in apoptotic cell death by facilitating the release of
apoptogenic factors. It was observed that Aβ in the presence of Ca2+
decreased the mitochondrial transmembrane potential and the
capacity of brain mitochondria to accumulate Ca2+ and induced a
complete uncoupling of respiration and an alteration of the
ultrastructural morphology of mitochondria characterized by swelling
and disruption of mitochondria cristae [41,42]. Altogether, these
results suggest a clear association between Aβ, mitochondrial
dysfunction, and alteration of Ca2+ homeostasis. Additionally diabe-
tes-related mitochondrial dysfunction is exacerbated by aging and/or
by the presence of Aβ, supporting the idea that diabetes and aging are
risk factors for the neurodegeneration induced by this peptide [43–
45]. Aging of diabetic mice induced an impairment of the respiratory
chain and a decrease on oxidative phosphorylation efﬁciency and in
the mitochondrial capacity to accumulate Ca2+. In the presence of
Aβ25–35 or Aβ40, the age-relatedmitochondrial effects are potentiated
[43]. Furthermore, we also observed that brain mitochondria isolated
from diabetic rats in the presence of Aβ40 produce higher levels of
H2O2 [45]. However, insulin and coenzyme Q10 (CoQ10) treatments
prevent the decline in mitochondrial OXPHOS efﬁciency and avoid an
increase in oxidative stress induced by Aβ [44].
Other studies from our laboratory also showed that pheochromo-
cytoma cells (PC12) exposed to Aβ40 and Aβ25–35 present mitochon-
drial dysfunction characterized by the inhibition of complexes I, III, and
IV of the mitochondrial respiratory chain [46]. Recently, Rhein et al.
[47] evaluated the mitochondrial respiratory functions and energy
metabolism in control and in human wild-type AβPP stably trans-
fected SH-SY5Y cells. The authors observed that complex IV activity
was signiﬁcantly reduced in AβPP cells. In contrast, a signiﬁcant
increase in the activity of complex III was observed. The authors
interpreted this increase as a compensatory response in order to
balance the defect of complex IV. However, this compensatory
mechanism did not prevent the strong impairment of total respiration
in AβPP cells. As a result, the respiration together with ATP production
decreased in the AβPP cells in comparisonwith the control cells [47]. A
study from our laboratory also shows that AD ﬁbroblasts present high
levels of oxidative stress and apoptotic markers when compared with
young and age-matched controls [2]. Furthermore, AD-type changes
could be generated in control ﬁbroblasts using N-methylprotopor-
phyrin to inhibit COX assembly indicating that the observed oxidative
damage was associated with mitochondrial dysfunction. The effects of
N-methylprotoporphyrin were reversed or attenuated by both lipoic
acid (LA) and N-acetyl cysteine (NAC) [11]. These results suggest that
mitochondria are important players in oxidative damage that occurs in
AD and that antioxidant therapies may be promising.
Interestingly, Abramov et al. [48] reported that Aβ causes a loss of
mitochondrial potential in astrocytes but not in neurons. Since thiseffect was prevented by antioxidants and reversed by provision of
glutamate and other mitochondrial substrates to complexes I and II,
they suggested that the depolarization reﬂects oxidative damage to
metabolic pathways upstream of mitochondrial respiration. However,
Paradisi et al. [49] demonstrated that astrocytes can protect neurons
from Aβ neurotoxicity, but when they interact directly with Aβ, the
protection is undermined and the neurotoxicity is enhanced.
It has also been shown that Ntera2 human teratocarcinoma (NT2
rh0+) cells exposed to Aβ25–35 release cytochrome c, with subse-
quent activation of caspases 9 and 3 [50]. Recently, Marques et al. [51]
investigated the effect of the AβPP Swedish double mutation
(K670M/N671L) on oxidative stress-induced cell death mechanisms
in PC12 cells. They observed an increased activity of caspase 3 due to
an enhanced activation of both intrinsic and extrinsic apoptotic
pathways, including activation of JNK pathway and an attenuation of
apoptosis by SP600125, a JNK inhibitor, through protection of
mitochondrial dysfunction and reduction of caspase 9 activity. These
results support the idea that the massive neurodegeneration at an
early age in familial AD patients could be a result of an increased
vulnerability of neurons through the activation of different apoptotic
pathways as a consequence of elevated levels of oxidative stress.
Yamamori et al. [52] reported that subtoxic concentrations (100–
500 nM) of Aβ1–42 can down-regulate the expression of the X-linked
inhibitor of apoptosis (XIAP) in human SH-SY5Y neuroblastoma cells
and the vulnerability to oxidative stress caused by Aβ42 is attenuated
by overexpression of XIAP suggesting that XIAP expression in
response to subtoxic, more physiological concentrations (100–
500 nM) of Aβ42 increases the vulnerability to oxidative stress. Song
et al. [53] investigated the possibility that overexpression of Bcl-2may
prevent Aβ-induced cell death through the inhibition of pro-apoptotic
activation of p38 mitogen-activated protein kinase (MAPK) and the
transcription factor nuclear factor-kappa B (NF-κB) in nerve growth
factor (NGF)-induced differentiated PC12 cells. These results suggest
that Bcl-2 overexpression protects against Aβ-induced cell death of
differentiated PC12 and its protective effect may be related to the
reduction of Aβ-induced activation of p38 MAPK and NF-κB. Tamagno
et al. [54] used differentiated SK-N-BE neurons to investigate
molecular mechanisms and regulatory pathways underlying apopto-
tic neuronal cell death elicited by Aβ1–40 and Aβ1–42 peptides as well
as the relationship between apoptosis and oxidative stress. They
observed that Aβ peptides, used at concentrations able to induce
oxidative stress, elicit a classic type of neuronal apoptosis involving
mitochondrial regulatory proteins and pathways (i.e., affecting Bax
and Bcl-2 protein levels as well as release of cytochrome c in the
cytosol), poly-ADP ribose polymerase (PARP) cleavage, and activation
of caspase 3. This pattern of neuronal apoptosis is signiﬁcantly
prevented by α-tocopherol and NAC and completely abolished by
speciﬁc inhibitors of stress-activated protein kinases (SAPK) such as
JNKs and p38 MAPK, involved in the early increase of p53 protein
levels. These results suggest that oxidative stress-mediated neuronal
apoptosis induced by Aβ operates by eliciting a SAPK-dependent
regulation of pro-apoptotic mitochondrial pathways involving both
p53 and Bcl2.
The studies presented above clearly show that mitochondrial
dysfunction is a key player in AD pathogenesis (Fig. 2).
4. Mitochondrial dysfunction and autophagy in AD
Macroautophagy (thereafter called autophagy) is crucial for
neuronal homeostasis, predominantly as housekeeping process to
prevent accumulation of protein aggregates and defective organelles
(Fig. 3). Neuronal homeostasis depends on balanced, bidirectional
trafﬁcking of intracellular constituents between distal neurites and
the cell soma. In neurons, autophagosomes and endosomes that fuse
in the distal axon must be retrogradely transported to the soma in
order to fuse with lysosomes and degrade their contents [55,56]. Thus,
Fig. 3. The autophagic process. The process by which the cell breaks down aggregates of
proteins and defective organelles is called (macro)autophagy. These aggregates and
defective organelles are engulfed by a double membrane to separate it from the rest of
the cell (1); the resulting membrane-enclosed bubble of cytosol and the cells'
constituents they contain becomes an autophagosome (2). The autophagosome then
fuses with a lysosome that contains several enzymes that can break down the cellular
components (3). These enzymes only work in a very acidic environment, so the pH
inside lysosomes is much lower that the neutral pH in the rest of the cell. Once the
contents of the autophagosome are delivered to the lysosome, its enzymes break down
those constituents, which can then be recycled for new use within the cell (4–7).
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trafﬁcking would be predicted to have terrible consequences for
autophagic ﬂux and neuronal homeostasis. Indeed, evidence is
mounting that autophagic pathways are vitally important for the
maintenance of neuronal health, particularly in the context of
degenerative diseases. Direct evidence for the vital role of autophagy
comes from studies of mice which revealed that mice lacking Atg5
[57] or Atg7 [58] showed severe neurodegeneration in the CNS.
During recent years, accumulating evidence has been obtained that
mitochondria also may be subject to selective degradation (mito-
phagy). How mitochondria are selectively sequestered into autopha-
gosomes is still largely unknown. Studies in Saccharomyces cerevisiae
have shown that excess or damaged mitochondria can be selectively
eliminated and Uth1 and Aup1 are involved in this process [59–61].
Uth1 is located at the mitochondria outer membrane, whereas Aup1
resides in the intermembrane space of this organelle. Recent data
obtained in yeast suggest that mitochondrial ﬁssion and fusion
processes are important to segregate functional from non-functional
regions followed by subsequent autophagic degradation of the non-
functional parts [62]. Recently, Kanki and Klionsky [63] found that
ATG11, a gene that is essential only for selective autophagy, is also
essential for mitophagy. In addition, the authors found that mito-
phagy is blocked even under severe starvation conditions, if the
carbon source makes mitochondria essential for metabolism [63].
These ﬁndings suggest that the degradation of mitochondria is a
tightly regulated process and that these organelles are largely
protected from nonspeciﬁc autophagic degradation.
During brain aging, many mitochondria undergo enlargement and
structural disorganization, while lysosomes gradually accumulate the
nondegradable, polymer lipofuscin. It is believed that this is a result
not only of continuous oxidative stress, causing oxidation of
mitochondrial constituents and autophagocytosed material, but also
of the inherent inability of cells to completely remove oxidatively
damaged structures. Although lipofuscin-loaded lysosomes continue
to receive newly synthesized lysosomal enzymes, the pigment is
nondegradable. Therefore, lipofuscin accumulation may greatly
diminish lysosomal degradative capacity by preventing lysosomal
enzymes from targeting functional autophagosomes, further limitingmitochondrial recycling. Based on ﬁndings that autophagy is
diminished in lipofuscin-loaded cells and that cellular lipofuscin
content positively correlates with oxidative stress and mitochondrial
damage, Terman and Brunk [56] proposed the mitochondrial–
lysosomal axis theory of aging, according to which mitochondrial
turnover progressively declines with age, resulting in increased
oxidative damage, accumulation of damaged organelles and lipofus-
cin, decreased ATP production, release of apoptotic factors, and,
eventually, cell death (Fig. 4).
Although the exact role of autophagy in AD is not fully deﬁned,
recent studies have provided some insights. Nixon et al. [64]
identiﬁed autophagosomes and other prelysosomal autophagic
vacuoles in AD brains particularly within neuritic processes. In
dystrophic neurites, the predominant organelles were autophago-
somes, multivesicular bodies, multilamellar bodies, and cathepsin-
containing autophagolysosomes. Autophagy was evident in the
perikarya of affected neurons, particularly in those with neuroﬁ-
brillary pathology where it was associated with a relative depletion
of mitochondria and other organelles [64]. Accordingly, we have
recently shown that autophagocytosis of mitochondria is prominent
in AD [65,66]. We demonstrated that LA, a sulfur-containing
cofactor required for the activity of enzyme complexes central to
respiratory metabolism, was localized in pyramidal neurons in
cases of AD. Although we observed an age-dependent decrease in
LA-binding proteins, we found profound alterations between AD
and control cases in terms of LA distribution. We suspect that this
could be related to the fragmentation of mitochondrial enzyme
complexes. Indeed, electron microscopic analysis showed that, in
addition to mitochondria, LA immunoreactivity is also localized in
autophagic vacuoles and lipofuscin, whereas control cases present
little labeling in the same compartments. Consistent with these
observations, light microscopic analysis showed that neurons from
cases of AD present granular immunoreactivity, consistent with
autophagic vacuoles and increased cytoplasmic staining, when
compared with age-matched and young controls [65]. Overall,
these observations are in accordance with previous studies from
our laboratory and others showing that neurons with increased
oxidative damage [5] in AD have a striking and signiﬁcant increase
in mtDNA in neuronal cytoplasm and in vacuoles associated with
lipofuscin [18], the proposed site of mitochondrial degradation by
autophagy [67]. Consistent with this, we also observed that COX-1,
a mitochondrial protein, was increased in the cytosol and
associated with mitochondria undergoing phagocytosis [65]. Alto-
gether, these observations support the notion that vulnerable
neurons in AD have increased mitochondrial degradation products,
suggesting either a greater turnover of mitochondria by autophagy
within the cell body and/or a reduction of proteolytic turnover
leading to accumulation of products of mitochondria degradation.
Interestingly, accumulation of nonprotein components (LA and
mtDNA) in the lysosomal pathway is striking while a protein
component (COX-1) is absent from these structures. Considering
the role of cytosolic mitochondria components in regulating
apoptosis and the observation of increased mitochondrial compo-
nents in the cytosol, possibly resulting from leakage of autophagic
components [68], these results merit further investigation. Besides
the involvement in mitochondrial turnover, the large autophagic
vacuoles found in neurons of AD brains have several other possible
implications for AD pathogenesis.
Autophagic vacuoles have been recently shown to contain AβPP
as well as the secretase activities required to generate Aβ and are
particularly highly enriched in γ-secretase enzymatic activity and γ-
secretase complex components [69,70]. Aβ40, Aβ42, and βCTF have
been detected in puriﬁed autophagic vacuoles from livers of yeast
artiﬁcial chromosome transgenic mice overexpressing AβPP [69].
These observations suggest that accumulated autophagic vacuoles in
dystrophic neurites may also contribute to the local production of
Fig. 4. Schematic representation of the mitochondrial–lysosomal theory of aging. Neuronal cells accumulate damagedmitochondria and lipofuscin inclusions during aging. Oxidative
injury to mitochondrial biomolecules may disturb ﬁssion of somemitochondria, resulting in their enlargement. Large mitochondria are likely to be poorly autophagocytosed, leading
to further damage and enlargement. Lysosomes progressively accumulate lipofuscin pigment. Lipofuscin-containing lysosomes attract large amounts of newly synthesized lysosomal
enzymes, which, however, fail to degrade the undegradable pigment. Consequently, it may result in insufﬁcient supply of lysosomal enzymes for autophagocytosis, further lessening
mitochondrial recycling. Poorly functioning enlarged mitochondria and lipofuscin-ﬁlled lysosomes gradually displace normal organelles, eventually causing decreased ATP
production and failing autophagocytosis, resulting in degeneration and death of neuronal cells. A, autophagosome; ATP, adenosine triphosphate; F, mitochondrial ﬁssion; L,
lipofuscin; Ly, lysosomes; ROS, reactive oxygen species.
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the neuropil could be a signiﬁcant source of Aβ overproduction in
AD brain.
Recently, Hung et al. [71] observed that treatment with Aβ25–35,
Aβ42, or serum starvation induced strong autophagy response in SH-
SY5Y overexpressing EGFP-LC3. Confocal double-staining image
showed that exogenous application of Aβ42 in medium caused the
colocalization of Aβ42 with LC3 in neuronal cells. Concomitant
treatment of Aβ with a selective α7nAChR antagonist, α-bungar-
otoxin (α-BTX), enhanced Aβ-induced neurotoxicity in SH-SY5Y cells.
On the other hand, nicotine (nAChR agonist) enhanced the autophagic
process and also inhibited cell death following Aβ application. In
addition, nicotine but not α-BTX increased primary hippocampal
neuronal survival following Aβ treatment. Furthermore, using Atg7
siRNA to inhibit autophagosome formation in an early step or
α7nAChR siRNA to knock-down α7nAChR signiﬁcantly enhanced
Aβ-induced neurotoxicity. Confocal double-staining imaging shows
that nicotine treatment in the presence of Aβ enhanced the
colocalization of α7nAChR with autophagosomes. These results
suggest that α7nAChR may act as a carrier to bind with Aβ and
internalize into cytoplasm and further inhibit Aβ-induced neurotox-
icity via autophagic degradation pathway. These results also suggest
that autophagy plays a neuroprotective role against Aβ-induced
neurotoxicity. Defect in autophagic regulation or Aβ-α7nAChR
transport system may impair the clearance of Aβ and enhance
neuronal death. Ling et al. [72] expressed human Aβ42 and Aβ40 in
Drosophila neurons. Aβ42 but not Aβ40 causes an extensive accumu-
lation of autophagic vesicles that become increasingly dysfunctional
with age. Aβ42-induced impairment of the degradative function, as
well as the structural integrity, of post-lysosomal autophagic vesicles
triggers a neurodegenerative cascade that can be enhanced by
autophagy activation or partially rescued by autophagy inhibition.
Compromise and leakage from post-lysosomal vesicles result in
cytosolic acidiﬁcation, additional damage to membranes and orga-
nelles, and erosive destruction of cytoplasm leading to eventual
neuron death. The authors indicate that neuronal autophagy initially
appears to play a pro-survival role that changes in an age-dependent
way to a pro-death role in the context of Aβ42 expression [72]. These
observations provide a mechanistic understanding for the differential
neurotoxicity of Aβ42 and Aβ40 and reveal an Aβ42-induced death
execution pathway mediated by an age-dependent autophagic–
lysosomal injury.These evidences suggest that autophagy is involved in AD
pathophysiology. However, it is not clear yet if autophagy plays a
causative role, a protective role or is a consequence of the disease
process itself.
5. Can autophagy be considered a therapeutic target in AD?
Autophagy is one of the most rapidly growing ﬁelds in biomedical
research. The autophagic process is crucial for cells homeostasis,
predominantly as housekeeping process to prevent accumulation of
protein aggregates and defective organelles. More recently, it has
become apparent that levels of autophagy are exquisitely regulated
and that autophagy-related processes play central roles in several
processes including development, aging, and neurodegeneration.
The role of autophagy as a mediator of cell death has become
generally accepted in some ﬁelds [73] but alternative interpretations
have been proposed [74]. Earlier studies used phosphoinositide 3-
kinase inhibitors to inhibit and thus implicate stress-induced
autophagy in a pro-death role [75,76]. Other studies used rapamycin
to demonstrate an important beneﬁcial role for autophagy in
aggregate clearance in neurodegenerative conditions [77]. However,
both classes of drugs may have diverse effects on cells that extend
beyond autophagy regulation to includemodulation of survival/death
kinases by 3-methyladenine [75] and regulation of protein synthesis
and differentiation through mTOR [78]. Thus, the issue of whether
autophagy observed in dying cells reﬂects a death mechanism, failed
adaptation, or epiphenomenon requires additional complementary
approaches to establish causality.
Until recently, autophagy has received limited attention in relation
to AD despite its importance as a mechanism for removing defective
organelles and potentially toxic proteins. Defective autophagy leads to
a progressive accumulation within neurons of lipofuscin, defective
mitochondria, and cytoplasmic protein aggregates. As a result of
lipofuscin accumulation, the proportion of functionally effective
structures declines, gradually decreasing adaptability of the biological
system. Along these lines, it is possible that lipofuscin deposition
hampers autophagic mitochondrial turnover, promoting the accumu-
lation of senescent mitochondria, which are deﬁcient in ATP
production but produce increased amounts of ROS. Increased
oxidative stress, in turn, further enhances damage to both mitochon-
dria and lysosomes, thus diminishing adaptability, triggering mito-
chondrial and lysosomal pro-apoptotic pathways, and culminating in
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generation and mediator of both cell survival and degenerative
phenomena [69–72], autophagy represents a new direction for
investigation into the pathogenesis and possible therapy of AD.
However, it is essential to clarify the role of autophagy (protective or
deleterious) in different stages of AD progression. Indeed, a more
complete understanding of (dys)function along the entire spectrum of
the autophagic process, from autophagosome formation through
clearance and regeneration of new cellular components, is necessary
to promote neuronal health and maximize therapeutic potentials.
6. Conclusions
Mitochondria have a wide variety of functions, including ATP
production and control of energy efﬁciency, calcium homeostasis, ROS
generation, and apoptotic signaling. Being a major intracellular source
of ROS, mitochondria are particularly vulnerable to oxidative stress.
Extensive literature exists supporting a causative role of mitochon-
drial dysfunction and oxidative stress in the pathogenesis of AD.
Furthermore, a link between mitochondrial dysfunction/oxidative
stress and autophagy has been reported to occur in AD. However, it is
not clear yet if autophagy plays a causative role or a protective role or
is a consequence of the disease process itself. Understanding the exact
role of autophagy in different stages of AD progression may help to
design more effective therapeutic strategies. Indeed, a central issue in
developing therapies for neurodegenerative diseases involves under-
standing why and when responses to stress or injury can help prevent
neuronal degeneration and death.
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